News
-
IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines
GENEVA – 26 June 2019 – The International Generic and Biosimilar medicines Association (IGBA) today released a revised report Trade Principles: Generic and Biosimilar Medicines which addresses how trade agreements can be designed to foster trade in generic and biosimilar medicines and… Read More -
Committing to Global Health: Balancing Access and Sustainability key to success
Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition,… Read More
-
Contribution of the generic and biosimilar medicines industries to the 2030 United Nations Agenda for Sustainable Development - Universal Health Coverage
Geneva, 20 May 2019 - Generic and biosimilar medicines have improved the quality of life of patients all over the world by increasing access to high-quality medicines. It is useful to report data that shows the actual impact of generic and… Read More -
IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus
Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
Vision and Mission
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
The IGBA
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
